For decades, Alzheimer’s disease has been framed as a one‑way slide, with treatments aiming only to slow the descent. Now a cluster of animal studies is challenging that assumption, showing that ...

Amyloid beta is a peptide that plays a central role in the neurodegenerative pathology of Alzheimer’s disease by aggregating into plaques in the brain. U.S. Food and Drug Administration (FDA) approved ...

Alzheimer's disease affects the brain in tragic and seemingly irreversible ways, but a new study gives hope that its ...

The drug is called NU-9, and a team from Northwestern University in the US tested it on mouse models of Alzheimer's disease.

Scientists reversed advanced Alzheimer's in mice using a compound that restores cellular energy. The breakthrough challenges ...

For over a century, Alzheimer's disease (AD) has been considered irreversible. Consequently, research has focused on disease ...

Multiple studies in humans and mouse models indicate that sleep disruptions raise the risk of Alzheimer’s disease (AD) by increasing the accumulation of disease-relevant proteins such as amyloid-beta ...

Talk about a closely watched study. Conference after conference, Roche scientists running the ongoing Brain Shuttle AD trial of trontinemab are dispensing morsels of news from sequential interim ...

An experimental drug called NU-9 has shown promise as an early intervention for Alzheimer's disease. | Drug Discovery And ...